Overview
CLLS market data
Price History
CLLS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.67 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.03 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -68.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.03 – $4.84 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $174.3M · P/B 4.56 · P/S 1.62.
Company News
Cellectis Q2 Adj. EPS $(0.19) Beats $(0.27) Estimate, Sales $6.904M Miss $13.225M EstimateBenzinga · Aug 6, 2026, 8:32 PM
Cellectis Presents Lasme-cel Phase 1 Data Showing Manageable Safety Profile With CRS Grade 3 In 4% Of Patients And Eti-cel Achieving 63% Complete Response In r/r B-NHLBenzinga · Jun 11, 2026, 7:10 AM
Cellectis shares are trading higher after the company announced that the FDA granted Regenerative Medicine Advanced Therapy designation to lasmecabtagene timgedleucelBenzinga · Jun 9, 2026, 8:36 PM
Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALLBenzinga · Jun 9, 2026, 8:32 PM
Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9Benzinga · May 28, 2026, 1:40 PM